Bosentan

Excerpt

Pulmonary arterial hypertension (PAH) contributes substantially to global morbidity and mortality due to progressive vascular remodeling and increased pulmonary vascular resistance. Endothelin 1 overexpression plays a central role in vasoconstriction, smooth muscle proliferation, and endothelial dysfunction in affected patients. Bosentan, a dual endothelin receptor antagonist, mitigates these pathogenic processes by competitively inhibiting endothelin A and B receptors, thereby reducing pulmonary arterial pressure and improving cardiac output.